Improved specificity of the PABA test with p-aminosalicylic acid (PAS).

Hoek, Frans J.; Bergh, F A van den; Elhorst, J.T.Klein; Meijer, J. L.; Timmer, Emily C.; Tytgat, G. N. J.

doi:10.1136/gut.28.4.468

Cited by 23 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reflecting exocrine pancreatic function, remained essentially unchanged during oc treotide treatment as compared to placebo [9,10], Furthermore, comparison of the re sults in acromegalics with those in healthy volunteers revealed excellent exocrine pan creatic function in the former on long-term octreotide treatment [9], The finding that pancreatic exocrine function was not seriously impaired is sup ported by the observation that clinical steatorrhoea and acute weight loss were noted in only 3 of 54 patients with acromegaly treated continuously with 100-300 pg octreotide daily for more than 1 month [11], Whether these results obtained in acromegalics can be extrapolated to other groups of patients on long-term octreotide treatment remains to be established. Kvols et al (12] observed steatorrhoea ranging from 8 to 25 g/24 h in 8 of 12 patients with metastatic carcinoid tu mours treated for 3-12 months at a dose of 150pg 3 limes daily, suggesting that the prevalence of fat malabsorption in this group of patients may be higher than that in acro megalics.…”

Section: Exocrine Pancreatic Functionmentioning

confidence: 99%

Pancreatic Exocrine and Gallbladder Function during Long-Term Treatment with Octreotide (SMS 201–995)

Hopman¹,

Liessum²,

Pieters³

et al. 1990

Digestion

View full text Add to dashboard Cite

Since octreotide (SMS 201–995, Sandostatin; Sandoz Pharmaceuticals) is a potent inhibitor of pancreatic exocrine secretion and gallbladder contraction, long-term treatment with this drug may theoretically result in impaired pancreatic function and gallstones. However, we observed excellent pancreatic exocrine function – as assessed by the PABA/PAS test – in acromegalics who received octreotide treatment for more than 6 months. Plasma cholecystokinin showed a significant, although blunted, postprandial response, which exceeded the threshold for gallbladder contraction in healthy controls. Remarkably, postprandial gallbladder contraction was completely abolished for at least 2 h during octreotide treatment. In contrast to other studies, none of 16 acromegalic patients on long-term octreotide treatment developed gallstones. Although the incidence of gallstones in patients on long-term octreotide treatment may be increased, the risk seems to be variable.

show abstract

Section: Exocrine Pancreatic Functionmentioning

confidence: 99%

Pancreatic Exocrine and Gallbladder Function during Long-Term Treatment with Octreotide (SMS 201–995)

Hopman¹,

Liessum²,

Pieters³

et al. 1990

Digestion

View full text Add to dashboard Cite

show abstract

“…1) Assessment of the absorption of markers that are hydrolyzed from conjugates by pancreatic enzymes and subsequently appearing in the urine or serum (NBT‐PABA test, pancreolauryl test) (18–23),…”

Section: Pancreatic Function Testsmentioning

confidence: 99%

Indirect Pancreatic Function Tests in Children

Walkowiak,

Nousia‐Arvanitakis,

Henker

et al. 2005

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

“…PABAX testing [11] is based on several principles. N-benzoyltyrosylparaaminobenzoic acid (bentiromide) is a synthetic peptide that has been used to assess pancreatic sufficiency [15,24,23,4,16]. When this peptide is exposed to endogenous chymotrypsin following oral administration, paraaminobenzoic acid (PABA) is released, which can then be measured in urine or blood to screen for maldigestion.…”

Section: Introductionmentioning

confidence: 99%